Abstract
To investigate whether the course of primary melanoma disease correlates with expression of the various components of the proteolytic plasminogen activation (PA) system, immunohistochemical stainings for activators of plasminogen (tissue type (tPA) and urokinase type (uPA)), inhibitors of plasminogen activation (type 1 (PAI-1) and type 2 (PAI-2)) and the receptor for uPA (uPAR) were performed on 214 routinely processed melanoma lesions. All lesions were primary cutaneous melanomas, minimally 1.5 mm thick, and derived from patients with only local disease at the moment of diagnosis (clinically stage II (T3–4N0M0), American Joint Committee on Cancer). Median patient follow-up was 6.1 years. Single variables as immunohistochemical staining results (extent of tumour cell staining, pattern of tumour cell staining and for some components also staining of stromal cells), histopathological and clinical parameters as well as treatment variables were analysed in order to assess their prognostic importance, in terms of time to recurrence, time to distant metastasis and duration of survival. The extent of tPA tumour cell positivity, categorized as 0–5%, 6–50% and 51–100%, appeared to be of importance for these end-points. Lesions with 51–100% tPA-positive tumour cells were found to have the best prognosis, whereas lesions with 6–50% tPA-positive tumour cells had the worst. Moreover, the prognostic significance of Breslow thickness, microscopic ulceration and sex was confirmed in this study. Multivariate analyses, incorporating these relevant factors, showed that the extent of tPA tumour cell positivity was an independent prognostic factor for distant metastasis-free interval (P= 0.012) and for the duration of survival (P= 0.043). © 2000 Cancer Research Campaign
Similar content being viewed by others
Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Allgayer H, Babic R, Grützner KU, Beyer BCM, Tarabichi A, Schildberg FW and Heiss MM (1998) Tumor-associated proteases and inhibitors in gastric cancer: analysis of prognostic impact and individual risk protease patterns. Clin Exp Metastasis 16: 62–73
Andreasen PA, Kjøller L, Christensen L and Duffy MJ (1997) The urokinase-type plasminogen activator system in cancer metastasis: a review. Int J Cancer 72: 1–22
Berney CR, Yang J, Fisher RJ, Russell PJ and Crowe PJ (1998) Correlates of urokinase-type plasminogen activator in colorectal cancer: positive relationship with nm23 and c-erbB-2 protein expression. Oncol Res 10: 47–54
Bindal AK, Hammoud M, Shi WM, Wu SZ, Sawaya R and Rao JS (1994) Prognostic significance of proteolytic enzymes in human brain tumors. J Neurooncol 22: 101–110
Cardinali M, Uchino R and Chung SI (1990) Interaction of fibrinogen with murine melanoma cells: covalent association with cell membranes and protection against recognition by lymphokine-activated killer cells. Cancer Res 50: 8010–8016
Chambers SK, Ivins CM and Carcangiu ML (1997) Expression of plasminogen activator inhibitor-2 in epithelial ovarian cancer: a favorable prognostic factor related to the actions of CSF-1. Int J Cancer 74: 571–575
Chambers SK, Ivins CM and Carcangiu ML (1998) Plasminogen activator inhibitor-1 is an independent poor prognostic factor for survival in advanced stage epithelial ovarian cancer patients. Int J Cancer 79: 449–454
Cox DR (1972) Regression models and life-tables. J R Stat Soc B 34: 187–220
Delbaldo C, Masouye I, Saurat J-H, Vassalli J-D and Sappino A-P (1994) Plasminogen activation in melanocytic neoplasia. Cancer Res 54: 4547–4552
de Vries TJ, Quax PHA, Denijn M, Verrijp KN, Verheijen JH, Verspaget HW, Weidle UH, Ruiter DJ and van Muijen GNP (1994) Plasminogen activators, their inhibitors, and urokinase receptor emerge in late stages of melanocytic tumor progression. Am J Pathol 144: 70–81
de Vries TJ, Mooy CM, van Balken MR, Luyten GPM, Quax PHA, Verspaget HW, Weidle UH, Ruiter DJ and van Muijen GNP (1995) Components of the plasminogen activation system in uveal melanoma – a clinico-pathological study. J Pathol 175: 59–67
de Vries TJ, van Muijen GNP and Ruiter DJ (1996) The plasminogen activation system in melanoma cell lines and in melanocytic lesions. Melanoma Res 6: 79–88
de Witte JH, Sweep CGJ, Klijn JGM, Grebenschikov N, Peters HA, Look MP, van Tienoven THH, Heuvel JJTM, Bolt-de Vries J, Benraad THJ and Foekens JA (1999) Prognostic value of tissue-type plasminogen activator (tPA) and its complex with the type-1 inhibitor (PAI-1) in breast cancer. Br J Cancer 80: 286–294
Duffy MJ, O'Grady P, Devaney L, O'Siorain L, Fennelly JJ and Lijnen HR (1988) Tissue-type plasminogen activator, a new prognostic marker in breast cancer. Cancer Res 48: 1348–1349
Duffy MJ, Maguire TM, McDermott EW and O'Higgins N (1999) Urokinase plasminogen activator: a prognostic marker in multiple types of cancer. J Surg Oncol 71: 130–135
Duggan C, Kramer MD, Barnes C, Elvin P, McDermott E, O'Higgins N and Duffy MJ (1997) Plasminogen activator inhibitory type 2 in breast cancer. Br J Cancer 76: 622–627
Engelberg H (1999) Actions of heparin that may affect the malignant process. Cancer 85: 257–272
Ferrier CM, van Geloof WL, de Witte JH, Kramer MD, Ruiter DJ and van Muijen GNP 1998a) Epitopes of components of the plasminogen activation system are re-exposed in formalin-fixed paraffin sections by different retrieval techniques. J Histochem Cytochem 46: 469–476
Ferrier CM, van Muijen GNP and Ruiter DJ 1998b) Proteases in cutaneous melanoma. Ann Med 30: 431–442
Ferrier CM, de Witte JH, Straatman H, van Tienoven DH, van Geloof WL, Rietveld FJR, Sweep CGJ, Ruiter DJ and van Muijen GNP (1999) Comparison of immunohistochemistry with immunoassay (ELISA) for the detection of components of the plasminogen activation system in human tumour tissue. Br J Cancer 79: 1534–1541
Francis JL, Biggerstaff J and Amirkhosravi A (1998) Hemostasis and malignancy. Semin Thromb Hemost 24: 93–109
Ganesh S, Sier CFM, Heerding MM, van Krieken JHJM, Griffioen G, Welvaart K, van de Velde CJH, Verheijen JH, Lamers CBHW and Verspaget HW (1996) Prognostic value of the plasminogen activation system in patients with gastric carcinoma. Cancer 77: 1035–1043
Grebenschikov N, Geurts-Moespot A, de Witte H, Heuvel J, Leake R, Sweep F and Benraad T (1997) A sensitive and robust assay for urokinase and tissue-type plasminogen activators (uPA and tPA) and their inhibitor type I (PAI-1) in breast tumor cytosols. Int J Biol Markers 12: 6–14
Gunji Y and Gorelik E (1988) Role of fibrin coagulation in protection of murine tumor cells from destruction by cytotoxic cells. Cancer Res 48: 5216–5221
Hsu DW, Efird JT and Hedley-Whyte ET (1995) Prognostic role of urokinase-type plasminogen activator in human gliomas. Am J Pathol 147: 114–123
Hu G-F, Riordan JF and Vallee BL (1994) Angiogenin promotes invasiveness of cultured endothelial cells by stimulation of cell-associated proteolytic activities. Proc Natl Acad Sci USA 91: 12096–12100
Huijzer JC, Uhlenkott CE and Meadows GG (1995) Differences in expression of metalloproteinases and plasminogen activators in murine melanocytes and B16 melanoma variants: lack of association with in vitro invasion. Int J Cancer 63: 92–99
Ito H, Yonemura Y, Fujita H, Tsuchihara K, Kawamura T, Nojima N, Fujimura T, Nose H, Endo Y and Sasaki T (1996) Prognostic relevance of urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitors PAI-1 and PAI-2 in gastric cancer. Virchows Arch 427: 487–496
Jänicke F, Schmitt M and Graeff H (1991) Clinical relevance of the urokinase-type and tissue-type plasminogen activators and of their type 1 inhibitor in breast cancer. Semin Thromb Hemost 17: 303–312
Kaplan EL and Meier P (1958) Nonparametric estimation from incomplete observations. J Am Stat Assoc 53: 457–481
Kim SJ, Shiba E, Taguchi T, Watanabe T, Tanji Y, Kimoto Y, Izukura M and Takai S-I (1997) Urokinase type plasminogen activator receptor is a novel prognostic factor in breast cancer. Anticancer Res 17: 1373–1378
Kim SJ, Shiba E, Kobayashi T, Yayoi E, Furukawa J, Takatsuka Y, Shin E, Koyama H, Inaji H and Takai S 1998a) Prognostic impact of urokinase-type plasminogen activator (PA), PA-inhibitor type-1, and tissue-type PA antigen levels in node-negative breast cancer; a prospective study on multicenter basis. Clin Cancer Res 4: 177–182
Kim SJ, Shiba E, Tsukamoto F, Izukura M, Taguchi T, Yoneda K, Tanji Y, Kimoto Y and Takai S-I 1998b) The expression of urokinase type plasminogen activator is a novel prognostic factor in Dukes B and C colorectal cancer. Oncol Rep 5: 431–435
Kobayashi H, Fujishiro S and Terao T (1994) Impact of urokinase-type plasminogen activator and its inhibitor type 1 on prognosis in cervical cancer of the uterus. Cancer Res 54: 6539–6548
Lansink M, Koolwijk P, van Hinsbergh V and Kooistra T (1998) Effect of steroid hormones and retinoids on the formation of capillary-like tubular structures of human microvascular endothelial cells in fibrin matrices is related to urokinase expression. Blood 92: 927–938
Markus G (1984) The role of hemostasis and fibrinolysis in the metastatic spread of cancer. Semin Thromb Hemost 10: 61–70
Meissauer A, Kramer MD, Schirrmacher V and Brunner G (1992) Generation of cell surface-bound plasmin by cell-associated urokinase-type or secreted tissue-type plasminogen activator: a key event in melanoma cell invasiveness in vitro. Exp Cell Res 199: 179–190
Mueller BM (1996) Different roles for plasminogen activators and metalloproteinases in melanoma metastasis. Curr Top Microbiol Immunol 213: 65–80
Mulcahy HE, Duffy MJ, Gibbons D, McCarthy P, Parfrey NA, O'Donoghue DP and Sheahan K (1994) Urokinase-type plasminogen activator and outcome in Dukes' B colorectal cancer. Lancet 344: 583–584
Nakanishi K, Kawai T, Torikata C, Aurues T and Ikeda T (1998) Urokinase-type plasminogen activator, its inhibitor, and its receptor in patients with upper urinary tract carcinoma. Cancer 82: 724–732
O'Reilly MS, Holmgren L, Cheng C and Folkman J (1996) Angiostatin induces and sustains dormancy of human primary tumors in mice. Nat Med 2: 689–692
Pappot H, Guldhammer Skov B, Pyke C and Grøndahl-Hansen J (1997) Levels of plasminogen activator inhibitor type 1 and urokinase plasminogen activator receptor in non-small cell lung cancer as measured by quantitative ELISA and semiquantitative immunohistochemistry. Lung Cancer 17: 197–209
Quax PHA, van Muijen GNP, Weening-Verhoeff EJD, Lund LR, Danø K, Ruiter DJ and Verheijen JH (1991) Metastatic behavior of human melanoma cell lines in nude mice correlates with urokinase-type plasminogen activator, its type-1 inhibitor, and urokinase-mediated matrix degradation. J Cell Biol 115: 191–199
Reuning U, Magdolen V, Wilhelm O, Fischer K, Lutz V, Graeff H and Schmitt M (1998) Multifunctional potential of the plasminogen activation system in tumor invasion and metastasis (review). Int J Oncol 13: 893–906
Rickles FR and Edwards RL (1983) Activation of blood coagulation in cancer: Trousseau's syndrome revisited. Blood 62: 14–31
Rønne E, Behrendt N, Ellis V, Ploug M, Danø K and Høyer-Hansen G (1991) Cell-induced potentiation of the plasminogen activation system is abolished by a monoclonal antibody that recognizes the NH2-terminal domain of the urokinase receptor. FEBS Lett 288: 233–236
Rønne E, Høyer-Hansen G, Brünner N, Pederson H, Rank F, Osborne CK, Clark GM, Danø K and Grøndahl-Hansen J (1995) Urokinase receptor in breast cancer tissue extracts. Enzyme-linked immunosorbent assay with a combination of mono- and polyclonal antibodies. Breast Cancer Res Treat 33: 199–207
Ruiter DJ, Ferrier CM, van Muijen GNP, Henzen-Logmans SC, Kennedy S, Kramer MD, Nielsen BS and Schmitt M (1998a) Quality control of immunohistochemical evaluation of tumour-associated plasminogen activators and related components. Eur J Cancer 34: 1334–1340
Ruiter DJ and van Muijen GNP (1998b) Markers of melanocytic tumour progression. J Pathol 186: 340–342
Ruppert C, Ehrenforth S, Scharrer I and Halberstadt E (1997) Protease levels in breast, ovary, and other gynecological tumor tissues: prognostic importance in breast cancer. Cancer Detect Prev 21: 452–459
Sakamoto T, Spee C, Scuric Z, Gordon EM, Hinton DR, Anderson WF and Ryan SJ (1998) Ability of retroviral transduction to modify the angiogenic characteristics of RPE cells. Graefes Arch Clin Exp Ophthalmol 236: 220–229
Sato Y, Okamura K, Morimoto A, Hamanaka R, Hamaguchi K, Shimada T, Ono M, Kohno K, Sakata T and Kuwano M (1993) Indispensable role of tissue-type plasminogen activator in growth factor-dependent tube formation of human microvascular endothelial cells in vitro. Exp Cell Res 204: 223–229
Sato T, Nishimura G, Yonemura Y, Nojima N, Ninomiya I, Fujimura T, Sugiyama K, Miwa K, Miyazaki I, Nonomura A and Yamaguchi Y (1995) Association of immuno-histochemical detection of urokinase-type plasminogen activator with metastasis and prognosis in colorectal cancer. Oncology 52: 347–352
Schaefer BM, Maier K, Eickhoff U, Bechtel M and Kramer MD (1996) α2-Antiplasmin and plasminogen activator inhibitors in healing human skin wounds. Arch Dermatol Res 288: 122–128
Schraffordt Koops H, Vaglini M, Suciu S, Kroon BBR, Thompson JF, Göhl J, Eggermont AMM, Di Filippo F, Krementz ET, Ruiter DJ and Lejeune FJ (1998) Prophylactic isolated limb perfusion for localized, high-risk limb melanoma: results of a multicenter randomized phases III trial. J Clin Oncol 16: 2906–2912
Shapiro RL, Duquette JG, Roses DF, Nunes I, Harris MN, Kamino H, Wilson EL and Rifkin DB (1996) Induction of primary cutaneous melanocytic neoplasms in urokinase-type plasminogen activator (uPA)-deficient and wild-type mice: cellular blue nevi invade but do not progress to malignant melanoma in uPA-deficient animals. Cancer Res 56: 3597–3604
Takei A, Tashiro Y, Nakashima Y and Sueishi K (1995) Effects of fibrin on the angiogenesis in vitro of bovine endothelial cells in collagen gel. In Vitro Cell Dev Biol 31: 467–472
Takeuchi Y, Nakao A, Harada A, Nonami T, Fukatsu T and Takagi H (1993) Expression of plasminogen activators and their inhibitors in human pancreatic carcinoma: immunohistochemical study. Am J Gastroenterol 88: 1928–1933
Torzewski M, Sarbia M, Verreet P, Dutkowski P, Heep H, Willers R and Gabbert HE (1997) Prognostic significance of urokinase-type plasminogen activator expression in squamous cell carcinomas of the esophagus. Clin Cancer Res 3: 2263–2268
Umeda T, Eguchi Y, Okino K, Kodama M and Hattori T (1997) Cellular localization of urokinase-type plasminogen activator, its inhibitors, and their mRNAs in breast cancer tissues. J Pathol 183: 388–397
Welling TH, Huber TS, Messina LM and Stanley JC (1996) Tissue plasminogen activator increases canine endothelial cell proliferation rate through a plamin-independent, receptor-mediated mechanism. J Surg Res 66: 36–42
Westphal JR, van't Hullenaar R, Geurts-Moespot A, Sweep FCGJ, Verheijen JH, Bussemakers MMG, Askaa J, Eggermont AAM, Ruiter DJ and de Waal RMW (2000) Angiostatin generation by human tumor cell lines: involvement of plasminogen activators. Int J Cancer 86: 760–767
Yamashita J, Ogawa M, Yamashita S, Nakashima T, Saishoji T, Nomura K, Inada K and Kawano I (1993) Differential biological significance of tissue-type and urokinase-type plasminogen activator in human breast cancer. Br J Cancer 68: 524–529
Yamashita J, Ogawa M and Sakai K (1995) Prognostic significance of three novel biologic factors in a clinical trial of adjuvant therapy for node-negative breast cancer. Surgery 117: 601–608
Author information
Authors and Affiliations
Consortia
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Ferrier, C., Suciu, S., van Geloof, W. et al. High tPA-expression in primary melanoma of the limb correlates with good prognosis. Br J Cancer 83, 1351–1359 (2000). https://doi.org/10.1054/bjoc.2000.1460
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1054/bjoc.2000.1460
Keywords
This article is cited by
-
OSskcm: an online survival analysis webserver for skin cutaneous melanoma based on 1085 transcriptomic profiles
Cancer Cell International (2020)
-
Prognostic significance of VEGF and components of the plasminogen activator system in endometrial cancer
Journal of Cancer Research and Clinical Oncology (2020)
-
Tissue prognostic biomarkers in primary cutaneous melanoma
Virchows Archiv (2014)
-
Biomarkers: The Useful and the Not So Useful—An Assessment of Molecular Prognostic Markers for Cutaneous Melanoma
Journal of Investigative Dermatology (2010)
-
Revisiting the biological roles of PAI2 (SERPINB2) in cancer
Nature Reviews Cancer (2008)